PT Merck Tbk (ISX:MERK) Cyclically Adjusted Revenue per Share: Rp2,274.96 (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

ISX:MERK PT Merck Tbk ISX:MERK
87 GF Score
Price Rp3,800.00
GF Value Rp4,949.93
Valuation Modestly Undervalued
! 3 Warning Signs
View Full Analysis

What is PT Merck Tbk Cyclically Adjusted Revenue per Share?

PT Merck Tbk ISX:MERK -3.55% 87 Cyclically Adjusted Revenue per Share is Rp2,274.96 as of Mar. 2026. GuruFocus rates ISX:MERK with a GF Score™ of 87/100 and a GF Value™ of Rp4,949.93 (Modestly Undervalued). The stock has 3 warning signs investors should review.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

PT Merck Tbk's adjusted revenue per share for the three months ended in Mar. 2026 was Rp631.931. Add all the adjusted revenue per share for the past 10 years together and divide the count will get our Cyclically Adjusted Revenue per Share, which is Rp2,274.96 for the trailing ten years ended in Mar. 2026.

During the past 12 months, PT Merck Tbk's average Cyclically Adjusted Revenue Growth Rate was 2.60% per year. During the past 3 years, the average Cyclically Adjusted Revenue Growth Rate was -0.10% per year. During the past 5 years, the average Cyclically Adjusted Revenue Growth Rate was 0.30% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Revenue Growth Rate using Cyclically Adjusted Revenue per Share data.

During the past 13 years, the highest 3-Year average Cyclically Adjusted Revenue Growth Rate of PT Merck Tbk was 0.70% per year. The lowest was -1.90% per year. And the median was -0.10% per year.

As of today (2026-08-02), PT Merck Tbk's current stock price is Rp3800.00. PT Merck Tbk's Cyclically Adjusted Revenue per Share for the quarter that ended in Mar. 2026 was Rp2,274.96. PT Merck Tbk's Cyclically Adjusted PS Ratio of today is 1.67.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of PT Merck Tbk was 3.18. The lowest was 0.57. And the median was 1.65.


PT Merck Tbk  (ISX:MERK) Cyclically Adjusted Revenue per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Revenue per Share may underestimate the company's revenue. Cyclically Adjusted PS Ratio can seem to be too high even the actual PS Ratio is low.

For the Cyclically Adjusted PS Ratio, the revenue per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/S calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PS Ratio is also called CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.

PT Merck Tbk's Cyclically Adjusted PS Ratio of today is calculated as

Cyclically Adjusted PS Ratio=Share Price/Cyclically Adjusted Revenue per Share
=3800.00/2274.96
=1.67

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of PT Merck Tbk was 3.18. The lowest was 0.57. And the median was 1.65.


Be Aware

Cyclically Adjusted PS Ratio works better for cyclical companies. It gives you a better idea on the company's real revenue value.


PT Merck Tbk Cyclically Adjusted Revenue per Share Related Terms


PT Merck Tbk Cyclically Adjusted Revenue per Share Historical Data

* Premium members only.

The historical data trend for PT Merck Tbk's Cyclically Adjusted Revenue per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

PT Merck Tbk Cyclically Adjusted Revenue per Share Chart

PT Merck Tbk Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Cyclically Adjusted Revenue per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 2,226.43 2,290.28 2,300.49 2,241.07 2,281.13

PT Merck Tbk Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Cyclically Adjusted Revenue per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 2,216.86 2,220.54 2,238.31 2,281.13 2,274.96

ISX:MERK vs ZTS, UTHR, VTRS: Cyclically Adjusted Revenue per Share Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, PT Merck Tbk's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


PT Merck Tbk Cyclically Adjusted PS Ratio vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, PT Merck Tbk's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where PT Merck Tbk's Cyclically Adjusted PS Ratio falls into.


ISX:MERK
87GF Score
PT Merck Tbk ISX:MERK
Cyclically Adjusted Revenue per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

PT Merck Tbk Cyclically Adjusted Revenue per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

What is Cyclically Adjusted Revenue per Share? How do we calculate Cyclically Adjusted Revenue per Share?

Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Revenue per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the revenue per share from 2001 through 2010.

We adjusted the 2001 revenue per share data with the total inflation from 2001 through 2010 to the equivalent revenue in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's revenue is $1 a share in 2001, then the 2001's equivalent revenue in 2010 is $1.4 a share. If Wal-Mart's revenue is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 revenue in 2010 is $1.35. So on and so forth, you get the equivalent revenue per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, PT Merck Tbk's adjusted Revenue per Share data for the three months ended in Mar. 2026 was:

Adj_RevenuePerShare= Revenue per Share /CPI of Mar. 2026 (Change)*Current CPI (Mar. 2026)
=631.931/136.5387*136.5387
=631.931

Current CPI (Mar. 2026) = 136.5387.

PT Merck Tbk Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201606 607.149 103.212 803.192
201609 511.985 104.142 671.252
201612 507.752 105.222 658.872
201703 706.096 106.476 905.458
201706 647.647 107.722 820.903
201709 651.338 108.020 823.297
201712 -705.969 109.017 -884.194
201803 315.565 110.097 391.355
201806 343.916 111.085 422.721
201809 369.190 111.135 453.583
201812 337.307 112.430 409.637
201903 364.200 112.829 440.734
201906 342.924 114.730 408.109
201909 404.435 114.905 480.582
201912 550.572 115.486 650.940
202003 362.158 116.252 425.356
202006 269.175 116.630 315.124
202009 350.410 116.397 411.047
202012 482.201 117.318 561.202
202103 565.536 117.840 655.276
202106 565.788 118.184 653.659
202109 623.329 118.262 719.663
202112 621.229 119.516 709.710
202203 673.139 120.948 759.908
202206 665.179 123.322 736.465
202209 601.944 125.298 655.943
202212 570.005 126.098 617.202
202303 582.881 126.953 626.894
202306 529.190 127.663 565.982
202309 630.230 128.151 671.478
202312 403.757 129.395 426.049
202403 556.911 130.607 582.204
202406 494.887 130.792 516.633
202409 630.652 130.361 660.539
202412 631.718 131.432 656.265
202503 480.271 131.948 496.979
202506 591.508 133.241 606.150
202509 745.431 133.819 760.581
202512 862.850 135.271 870.936
202603 631.931 136.539 631.931

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.

What does a Cyclically Adjusted Revenue per Share of Rp2,274.96 mean?
PT Merck Tbk (ISX:MERK) has a Cyclically Adjusted Revenue per Share of Rp2,274.96 as of Mar. 2026. Cyclically adjusted revenue per share represents the company's inflation-adjusted revenue per share over a 10-year period. View historical data on PT Merck Tbk and its competitors.
Is PT Merck Tbk's Cyclically Adjusted Revenue per Share too high?
PT Merck Tbk's current Cyclically Adjusted Revenue per Share is Rp2,274.96. Overall, PT Merck Tbk has a GF Score™ of 87/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does PT Merck Tbk's Cyclically Adjusted Revenue per Share compare to ZTS and UTHR?
PT Merck Tbk's Cyclically Adjusted Revenue per Share of Rp2,274.96 can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted Revenue per Share for a Drug Manufacturers company?
A good Cyclically Adjusted Revenue per Share depends on the Drug Manufacturers industry context. However, Cyclically Adjusted Revenue per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted Revenue per Share mean?
A high Cyclically Adjusted Revenue per Share can signal that a stock is expensive relative to its fundamentals. Cyclically adjusted revenue per share represents the company's inflation-adjusted revenue per share over a 10-year period. View historical data on PT Merck Tbk and its competitors. PT Merck Tbk's current Cyclically Adjusted Revenue per Share is Rp2,274.96. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is PT Merck Tbk stock overvalued right now?
Based on GuruFocus' analysis, PT Merck Tbk (ISX:MERK) is currently considered Modestly Undervalued. The stock's GF Value™ is Rp4,949.93, compared to a current price of Rp3,800.00 — trading 23.2% below its estimated fair value. The current Cyclically Adjusted Revenue per Share is Rp2,274.96. PT Merck Tbk's overall GF Score™ is 87/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted Revenue per Share calculated?
Cyclically Adjusted Revenue per Share is calculated from a company's financial statements. For PT Merck Tbk (ISX:MERK), the current Cyclically Adjusted Revenue per Share is Rp2,274.96 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is PT Merck Tbk (ISX:MERK) Overvalued in 2026?

Based on GuruFocus' analysis, PT Merck Tbk stock appears to be undervalued. The current stock price of Rp3,800.00 is trading 23.2% below its estimated GF Value™ of Rp4,949.93. GuruFocus considers PT Merck Tbk to be Modestly Undervalued.

Key valuation signals for ISX:MERK:

  • Cyclically Adjusted Revenue per Share: Rp2,274.96
  • GF Value™: Rp4,949.93 vs. price of Rp3,800.00 (23.2% below fair value)
  • GF Score™: 87/100 with 3 warning signs

No single metric tells the full story. See the ISX:MERK stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


PT Merck Tbk Business Description

Address Jalan T.B. Simatupang No. 8, Pasar Rebo, Jakarta Timur, IDN, 13760
PT Merck Tbk engages in the manufacture and sale of pharmaceutical products in Indonesia. The company operates in three segments: Biopharma, Consumer Health, and Others. The company offers pharmaceutical and biological prescription medicines for colorectal cancer, head and neck tumors, multiple sclerosis, infertility, growth hormone disorders, cardiovascular disorders, diabetes, as well as thyroid disorders such as hypothyroidism.
87GF Score

Get the complete analysis for ISX:MERK

Cyclically Adjusted Revenue per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

Rp3,800.00
Price
Rp4,949.93
GF Value